Test Your Knowledge on Chronic Urticaria Assessment and Management
Reviewed by: HU Medical Review Board | Last reviewed: October 2026 | Last updated: October 2026
Two guidelines published in 2026 updated how chronic urticaria is assessed and when treatment is escalated. These 5 questions cover disease control scoring, the antihistamine ceiling, autoimmune endotypes, inducible urticaria testing, and where current therapies act. Each answer includes a brief rationale and its source.
Clinical Challenge
Which Urticaria Control Test (UCT) score marks the cutoff below which chronic urticaria is considered uncontrolled?
Clinical Challenge
In chronic urticaria that does not respond to a standard-dose second-generation H1-antihistamine, what is the maximum updosing supported by the 2026 guidelines?
Clinical Challenge
A patient with severe antihistamine-refractory chronic spontaneous urticaria (CSU) and Hashimoto thyroiditis has low total immunoglobulin E (IgE), elevated IgG anti-thyroid peroxidase, and basopenia. Which endotype does this profile suggest?
Clinical Challenge
Wheals appear within minutes of cold wind exposure or holding iced drinks. Which test best confirms the diagnosis and quantifies the trigger threshold?
Clinical Challenge
At which step does Bruton tyrosine kinase (BTK) inhibition act in CSU?


